Li Jian-Fu, Wang Qing-Bo, Li Yu-Kai, Liang Yu-Bo, Chen Xing-Ming, Lu Qi-Yu, Ke Yang
Department of General Surgery, The First People's Hospital of Dali City, Dali 671000, Yunnan Province, China.
Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, Yunnan Province, China.
World J Gastroenterol. 2025 Jun 21;31(23):107554. doi: 10.3748/wjg.v31.i23.107554.
This letter comments on the recently published article in the , in which the authors demonstrated a strong link between lymphangiogenesis and the process of platelet adherence, aggregation, and activation by employing a rat model of liver cirrhosis caused by bile duct ligation (BDL). The authors applied both gain and loss of function approach by using platelet-rich plasma and vascular endothelial growth factor 3 receptor inhibitor MAZ-51 to activate and inhibit angiogenetic signaling in BDL rat model, respectively, to verify the crucial function of lymphangiogenesis in the development of liver cirrhosis and portal hypertension (PHT). In clinical practice, platelet transfusion has been applied to improve liver function in patients suffering from chronic liver disease and cirrhosis. Therefore, this study provides support for the application of platelet transfusion or pharmacological intervention of lymphangiogenesis as novel therapeutic approaches for liver cirrhosis and PHT.
这封信是对最近发表在《 》上的文章的评论，作者在该文章中通过胆管结扎（BDL）诱导的大鼠肝硬化模型，证明了淋巴管生成与血小板黏附、聚集和激活过程之间存在紧密联系。作者分别采用富含血小板血浆和血管内皮生长因子3受体抑制剂MAZ-51，通过功能获得和功能丧失方法，在BDL大鼠模型中激活和抑制血管生成信号，以验证淋巴管生成在肝硬化和门静脉高压（PHT）发展中的关键作用。在临床实践中，血小板输注已被用于改善慢性肝病和肝硬化患者的肝功能。因此，本研究为血小板输注或淋巴管生成的药物干预作为肝硬化和PHT的新型治疗方法提供了支持。
